Novartis India
EVONILE • Pharmaceuticals & Biotechnology
Last Price
₹1714.30
Market Cap
₹4.24K Cr
Sector
Pharmaceuticals & Biotechnology
For educational/research use only. Not a recommendation to buy or sell.
At a glance
Sector: Novartis India (EVONILE) is an NSE-listed company in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry. NSE sector rotation chart
Sharia rating: Novartis India is rated Not halal by a specialist third-party provider. Full list of halal NSE stocks
29% below its 52-week high
Price trend
No reading
We don't have enough data to measure this for Novartis India right now.
Institutional activity
Positive
Trading patterns over recent weeks show some signs of institutions buying Novartis India (buying score 3/10, selling score 0/10).
Model rank
No reading
We don't have enough data to measure this for Novartis India right now.
Ease of trading
Low
Shares change hands easily; there are no signs of trading drying up (risk score 1/10).
Price vs profits
Loss-making
Novartis India did not make a profit last year, so there is no profit to compare the price against.
Company Information
About Novartis India (EVONILE)
Novartis India is an NSE-listed company operating in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry (ISIN INE234A01025). This page brings together the quantitative research signals our models compute for EVONILE: a model-estimated 1-day, 5-day and 21-day return outlook, momentum and trend indicators, institutional-activity context derived from observed trading flows, a snapshot of valuation and quality fundamentals, and the instrument's Sharia-compliance status. All figures are produced by statistical models from historical data and are intended for research and educational purposes.
To read the page, treat the model-estimated return outlook as a relative ranking signal rather than a forecast of price — higher scores reflect stronger model-estimated momentum and trend alignment, not a target or guarantee. The momentum and trend indicators describe how Novartis India's recent price action compares with its own history, while the fundamentals and institutional-activity context add longer-horizon and flow-based perspective. Nothing here is investment advice, a recommendation, or a solicitation to transact; always do your own research and consult a SEBI-registered adviser before making any decision.
The "typical range" we compare a price-to-earnings multiple against is a fixed band for all NSE stocks, not a sector-specific one. Everything on this page describes what our models measured; none of it is a recommendation to do anything.